Comparative Pharmacology
Head-to-head clinical analysis: RADICAVA versus RILUTEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RADICAVA versus RILUTEK.
RADICAVA vs RILUTEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radicava (edaravone) is a free radical scavenger that protects neuronal cells from oxidative stress by scavenging oxygen-derived free radicals and inhibiting lipid peroxidation in the central nervous system.
Exact mechanism unknown. Reduces glutamate-mediated excitotoxicity via inhibition of glutamate release and postsynaptic glutamate receptor blockade.
60 mg administered intravenously over 60 minutes once daily for 14 days, followed by a 14-day drug-free period; subsequent cycles repeat this 28-day cycle indefinitely.
50 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is approximately 4.5 hours. This short half-life supports twice-daily dosing; no accumulation occurs upon repeated administration.
Terminal half-life is 12 hours after repeated oral dosing (range 9-15 hours), increasing to ~20 hours in patients with mild hepatic impairment. Steady-state reached in 5 days.
Primarily renal excretion of unchanged drug (~88% of dose), with approximately 6% recovered in feces. Biliary excretion is negligible.
Primarily hepatic metabolism; 90% excreted in urine as metabolites (glucuronide and N-hydroxyriluzole) and 5% in feces. <1% unchanged in urine.
Category C
Category C
Neuroprotective Agent
Neuroprotective Agent